HOW IT WORKS
In vitro Absorption, distribution, metabolism and excretion studies can be conducted on tissues showing multicellular interactions in microphysiological systems.
The multiparametric data obtained from cell studies, assays, protein and gene expression and imaging is used for data analysis and predictive modelling of drug response.
The quantitative data is obtained through biosensors for microenvironment changes and physiological parameter analysis.
Cytochrome P450 studies are complimented with metabolism assays, expression profiling and transcriptomic analysis. A comprehensive data to understand the mechanistic of action or toxicity.
In-depth studies for cell proliferation, apoptosis, receptors & transporters.
Microfluidic device development involves CAD design, 3D printing, prototyping following by application optimisation and manufacturing.
Pharmacogenetics allows the study of the genetic variation due to ethnicity and gender that affects their response or adverse reaction to
medicines or xenobiotics.
Stemnovate has diverse bank of IPS lines that represent the human variability for pharmacogenetics studies.
Our multispecies cellular models allow in vitro studies for mechanism of action, transporters and signalling pathways. This reduced animal testing while the models benefit veterinary drug development and disease modelling.
Cytochromes P450 (CYPs) are the main enzymes involved in drug metabolism. These show huge expression variability among humans. We study CYP inhibition, induction, expression and polymorphism.
Tissue consists of specialised cells functioning while uniquely organised. We simulate this organisation for microphysiological studies. Eg, Liver tissue consists of hepatocytes, stellate and Kupffer cells.
In vitro Absorption, distribution, metabolism and excretion studies can be conducted on tissues showing multicellular interactions in microphysiological systems.
The multiparametric data obtained from cell studies, assays, protein and gene expression and imaging is used for data analysis and predictive modelling of drug response.
The quantitative data is obtained through biosensors for microenvironment changes and physiological parameter analysis.
Cytochrome P450 studies are complimented with metabolism assays, expression profiling and transcriptomic analysis. A comprehensive data to understand the mechanistic of action or toxicity.
In-depth studies for cell proliferation, apoptosis, receptors & transporters.
Microfluidic device development involves CAD design, 3D printing, prototyping following by application optimisation and manufacturing.
Pharmacogenetics allows the study of the genetic variation due to ethnicity and gender that affects their response or adverse reaction to
medicines or xenobiotics.
Stemnovate has diverse bank of IPS lines that represent the human variability for pharmacogenetics studies.
Our multispecies cellular models allow in vitro studies for mechanism of action, transporters and signalling pathways. This reduced animal testing while the models benefit veterinary drug development and disease modelling.
Cytochromes P450 (CYPs) are the main enzymes involved in drug metabolism. These show huge expression variability among humans. We study CYP inhibition, induction, expression and polymorphism.
Tissue consists of specialised cells functioning while uniquely organised. We simulate this organisation for microphysiological studies. Eg, Liver tissue consists of hepatocytes, stellate and Kupffer cells.
Stemnovate is a compliant organisation and all the procedures meet regulatory requirements.
Human Tissue Authority (HTA)
Stemnovate human cell slourcing is in compliance with the HTA, License since 2018. HTA is a regulatory body in the UK that regulates organisations that remove, store and use human tissue for research, medical treatment, post-mortem examination, education and training.
The Health and Safety Executive is a UK government agency responsible for the encouragement, regulation and enforcement of workplace health, safety and welfare, and for research into occupational risks in Great Britain. Stemnovate operations are compliant for Class-2 contained use (Genetically modified organisms (contained use) regulations 2014.
IPS technology license
Stemnovate obtained commercial license for IPS technology in 2018
Our clients say
You are doing some amazing and important work at Stemnovate, we are happy to be associated with your project.
Thank you for your presentations, they were really great and stimulating. I am very happy we met and that we could get the cells in culture!
CASE STUDIES
Prof Ciro Semprebon will be working in partnership with Stemnovate on the prestigious EPSRC grant project for advancing SLIPS technology.
Stemnovate has partnered with multinational collaborators on a project coordinated by MEDES Institute of space medicine and physiology.